Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey J Buda

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Frontiers in Pharmacology|July 26, 2018
A Double-Blind, Placebo-Controlled Trial Demonstrating the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336F Ivy Carroll, Thomas R Kosten, Jeffrey J Buda, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 29, 2015
A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTicJeffrey J Buda, F I Carroll, Thomas R Kosten, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 17, 2006
Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overviewJohn A Bartlett, Jeffrey J Buda, Birgitta von Scheele, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Frontiers in Pharmacology|July 26, 2018
A Double-Blind, Placebo-Controlled Trial Demonstrating the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336F Ivy Carroll, Thomas R Kosten, Jeffrey J Buda, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 29, 2015
A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTicJeffrey J Buda, F I Carroll, Thomas R Kosten, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 17, 2006
Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overviewJohn A Bartlett, Jeffrey J Buda, Birgitta von Scheele, et al.
Pageof 1